Literature DB >> 25648873

Reproducibility over time and effect of low-dose aspirin on soluble P-selectin and soluble CD40 ligand.

Vanessa Valdes1, Michael A Nardi, Lindsay Elbaum, Jeffrey S Berger.   

Abstract

Platelet markers [soluble CD40 ligand (sCD40L) and soluble p selectin (sPselectin)] are associated with platelet activation and cardiovascular events. We sought to investigate the reproducibility of these markers over time and the effect of low-dose aspirin on sCD40L and sPselectin in plasma and serum. Following an overnight fast, 40 healthy volunteers had weekly phlebotomy and were administered aspirin 81 mg/day between weeks 3 and 4. Reproducibility over time was assessed by coefficient of variation (CV) and inter-class correlation coefficient. Correlation between markers was assessed using Pearson r statistic. Difference between levels pre- and post-aspirin was measured with Wilcoxon signed-rank test. Data are presented as median (interquartile range). sCD40L and sPselectin measurements were reproducible over time in plasma and serum (CV < 10 %). Measurement of sCD40L and sPselectin in plasma correlated with levels in serum before aspirin and after aspirin. There was no significant correlation between sCD40L and sPselectin. After 1-week of aspirin 81 mg/day, there was a reduction in sCD40L and sPselectin in serum and plasma, respectively. Soluble CD40L and sPselectin are independent markers that are reproducible over time in both plasma and sera and are reduced by 1-week of low-dose aspirin.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25648873      PMCID: PMC5514372          DOI: 10.1007/s11239-015-1179-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  19 in total

1.  Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma.

Authors:  J Thom; G Gilmore; Q Yi; G J Hankey; J W Eikelboom
Journal:  J Thromb Haemost       Date:  2004-11       Impact factor: 5.824

2.  Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions.

Authors:  Silvia Riondino; Francesca Martini; Francesca La Farina; Antonella Spila; Fiorella Guadagni; Patrizia Ferroni
Journal:  Clin Biochem       Date:  2010-01-11       Impact factor: 3.281

3.  Platelet P-selectin facilitates atherosclerotic lesion development.

Authors:  Peter C Burger; Denisa D Wagner
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

Review 4.  Hypothesis: is soluble P-selectin a new marker of platelet activation?

Authors:  A D Blann; G Y Lip
Journal:  Atherosclerosis       Date:  1997-02-10       Impact factor: 5.162

5.  Soluble P-selectin and the risk of future cardiovascular events.

Authors:  P M Ridker; J E Buring; N Rifai
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

Review 6.  Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data.

Authors:  Gaurav Sharma; Jeffrey S Berger
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

7.  Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease.

Authors:  Peter J Mason; Subrata Chakrabarti; Anne A Albers; Sybille Rex; Olga Vitseva; Sonia Varghese; Jane E Freedman
Journal:  Am J Cardiol       Date:  2005-09-19       Impact factor: 2.778

8.  Influence of pre-analytical and analytical factors on soluble CD40L measurements.

Authors:  Nerea Varo; Rebecca Nuzzo; Cristina Natal; Peter Libby; Uwe Schönbeck
Journal:  Clin Sci (Lond)       Date:  2006-11       Impact factor: 6.124

9.  Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk.

Authors:  Eugene R Ahn; Gabriella Lander; Wenche Jy; Carlos J Bidot; Joaquin J Jimenez; Lawrence L Horstman; Yeon S Ahn
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

Review 10.  The CD40/CD40 ligand system: linking inflammation with atherothrombosis.

Authors:  Charalambos Antoniades; Constantinos Bakogiannis; Dimitris Tousoulis; Alexios S Antonopoulos; Christodoulos Stefanadis
Journal:  J Am Coll Cardiol       Date:  2009-08-18       Impact factor: 24.094

View more
  8 in total

Review 1.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

2.  Association between P-selectin levels and left atrial blood stasis in patients with nonvalvular atrial fibrillation.

Authors:  W E Wysokinski; K P Cohoon; R M Melduni; M Mazur; N Ammash; T Munger; E Konik; T McLeod; Izabeal Gosk-Bierska; R D McBane
Journal:  Thromb Res       Date:  2018-10-10       Impact factor: 3.944

3.  Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study.

Authors:  Jan K Nowak; Irena Wojsyk-Banaszak; Edyta Mądry; Andrzej Wykrętowicz; Patrycja Krzyżanowska; Sławomira Drzymała-Czyż; Agata Nowicka; Andrzej Pogorzelski; Ewa Sapiejka; Wojciech Skorupa; Mariusz Szczepanik; Aleksandra Lisowska; Jaroslaw Walkowiak
Journal:  Lung       Date:  2017-06-23       Impact factor: 2.584

4.  Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach.

Authors:  Lucas B Cofer; Tessa J Barrett; Jeffrey S Berger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-09-01       Impact factor: 10.514

5.  Proteomic profiling identifies key differences between inter-stage infants with single ventricle heart disease and healthy controls.

Authors:  Benjamin S Frank; Ludmila Khailova; Lori Silveira; Max B Mitchell; Gareth J Morgan; Elena W Y Hsieh; Michael V DiMaria; Mark Twite; Jelena Klawitter; Jesse A Davidson
Journal:  Transl Res       Date:  2020-10-09       Impact factor: 7.012

6.  Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization.

Authors:  Thomas Gremmel; Andrew L Frelinger; Alan D Michelson
Journal:  PLoS One       Date:  2015-08-03       Impact factor: 3.240

7.  Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.

Authors:  Y C Lau; Q Xiong; P Ranjit; G Y H Lip; A D Blann
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

Review 8.  The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease.

Authors:  Laura A Bosmans; Lena Bosch; Pascal J H Kusters; Esther Lutgens; Tom T P Seijkens
Journal:  J Cardiovasc Transl Res       Date:  2020-03-28       Impact factor: 4.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.